CME

RED FLAG: ABSENT

CME Group shows no signs of critical liquidity, compromised governance, unsustainable debt or imminent binary regulatory risk. The financial position is solid, with positive net cash ($4.5B cash vs $3.8B long-term debt) and robust TTM FCF above $4B.

AI DISRUPTION RISK: LOW

Artificial intelligence is not able to replace CME's core functions: centralized clearing, liquidity concentration, collateral efficiency and regulated network effect. AI acts as an enabler for institutional clients — improving surveillance, risk management and product design — with the net effect of increasing volumes on the platform, not eroding them.

B1.1 — Leadership and systemic role: 9.50

CME Group is the critical infrastructure of the global financial system for derivatives risk management. It holds a virtual monopoly on futures linked to U.S. interest rates (SOFR, Treasury), North American agricultural contracts and major equity indices. 2025 marked a record in average daily volumes (ADV), with double-digit growth across multiple asset classes. Its systemic centrality — as both price discovery venue and clearing house at the same time — is difficult for any competitor, regulated or unregulated, to challenge.

B1.2 — Customers and barriers to entry: 9.00

Barriers to entry are structurally insurmountable: massive capital requirements, multi-year regulatory authorizations and, above all, the "gravity of liquidity". Institutional traders operate on CME because that is where the deepest liquidity pool resides, with the tightest spreads and the largest open interest — a self-reinforcing advantage. Cross-margining between products from different asset classes adds a further capital-efficiency advantage that no new entrant can replicate without equivalent critical mass. Customer lock-in is structural and increasing.

B1.3 — Business economics: 9.00

The model is exceptionally scalable: FY2025 revenue reached $6.52B with an operating margin of 64.9% and net income of $4.07B. Long-term ADV CAGR is above 7%, while adjusted net income has compounded at over 12% annually. The technology infrastructure is largely amortized, meaning that each additional contract traded generates extremely high incremental margins. Diversification across six asset classes protects the model from periods of low volatility in individual segments.

B1.4 — Balance sheet and resilience: 8.75

The balance sheet is a fortress: $4.5B of cash versus $3.8B of long-term debt, Debt/Equity below 14% and TTM FCF of $4.2B. The clearing-house function — with initial and variation margins collected from counterparties — protects CME from direct exposure to credit risk. The capital structure is conservative and cash generation capacity allows the company to remunerate shareholders abundantly while maintaining flexibility for acquisitions and strategic investments.

B2.1 — Sector cycle (Current Phase): 8.00

The regulated derivatives sector is in a tailwind phase with at least 4 out of 5 positive cyclical factors: upward aggregate earnings estimate revisions, sustained revenue growth trend (2025 record across several asset classes), favorable supply/demand dynamics with continuous launches of new products, low sector credit stress and stable regulatory regime in the U.S. The only partially negative factor is the possibility of normalization in macro volatility, which nevertheless appears structurally elevated in the current context of geopolitical uncertainty and monetary-policy transition.

B2.2 — Structural trends (Medium/Long Term): 8.00

The regulated derivatives market benefits from robust structural drivers: secular TAM growth for institutional risk management, expansion of global hedging mandates, integration of crypto markets into the regulated perimeter (CME has launched futures on AVAX and SUI with 24/7 trading expected from May 2026) and the arrival of more than 50 single stock futures contracts on S&P 500 stocks in the second half of 2026. The growing financialization of the global economy and increased institutionalized retail participation through micro products support structural growth well above nominal GDP.

B2.3 — Competitive positioning in the cycle: 8.50

CME captures the current macro regime optimally: its dominant exposure to interest-rate futures (SOFR, Treasury) positions it as a direct beneficiary of uncertainty over global monetary policy, with volumes in this segment at all-time highs. Compared with direct peers (ICE, Nasdaq Exchange), CME has very low beta (0.18-0.30) with superior pricing power on its proprietary contracts, thanks to the quasi-monopoly over fundamental benchmarks that market participants cannot avoid.

B2.4 — Specific risks (Exogenous): 7.75

Systemic risks are managed with strict frameworks: centralized clearing with margin collection drastically reduces counterparty risk. The main exogenous risk remains a prolonged period of low macro volatility that would compress volumes on rates and indices. Regulatory risk — although always present — has historically been benign toward U.S. national marketplaces of systemic importance. Risks on new crypto products and competition from alternative exchanges are assessed as low-probability in the short-medium term.

B3.1 — Intrinsic Fair Value: 5.57

The four main valuation sources produce estimates that are divergent in magnitude, but consistent in direction: the stock trades at a premium to intrinsic fair value. DCF models are affected by CME's capital-light structure — with very low capex and high FCF — which makes results sensitive to terminal growth rate and discount rate assumptions.

At the current price of $295.30, the weighted fair value of $251.05 implies a premium of about 17.6%. All four sources agree in indicating overvaluation, with dispersion of 32.2% — entirely directional — which generates no penalty. The Excellence Premium is applied by virtue of the Business Score of 9.06, which reflects the structural quality of the moat and earnings predictability, factors that standard DCF models tend to underweight.

> 📐 Premium +17.6% → base score 4.51 | dispersion 32.2% DIRECTIONAL → penalty 0 | Excellence Premium +1.06 (Business Score 9.06/10) → final score 5.57

Score includes Excellence Premium +1.06 (Business Score 9.06/10) — cap 6.50 not applied.

B3.2 — Analyst Consensus: 4.33

The sell-side consensus (3-month window, source TipRanks) is moderately positive in rating terms — 6 Buy out of 12 — but the average target of $285.70 is below the current price of $295.30, implying 3.2% downside. This signal is the weakest in the entire price analysis: analysts recognize the quality of the business but struggle to justify current multiples with meaningful upside in the short term.

> 📐 Consensus (6/12 Buy, 50%) → Consensus_Score 4.67 | downside −3.2% → Upside_Score 4.00 | average → 4.33

B3.3 — Relative Valuation: 5.50

With a TTM P/E of 26.46x, CME trades substantially in line with its 5-year historical average (about 26x) and slightly below the average of direct peers in the Capital Markets segment (about 28x). The framework's AND condition — simultaneous discount to both historical average and peers — is not satisfied: the historical multiple is almost identical to the current one, removing any relative discount signal. The peer comparison, if taken in isolation, would be slightly favorable, but not enough to justify a high score in the absence of the combined condition.

B3.4 — FCF & Net Shareholder Yield: 8.00

CME remunerates shareholders through a hybrid structure consisting of a regular quarterly dividend and a variable annual dividend linked to fiscal-year results. In the TTM (April 2025–April 2026), cash payments made include four quarterlies ($1.25+$1.25+$1.25+$1.30 = $5.05/share) and the FY2025 variable dividend ($6.15/share, paid March 2026), for a total of $11.20/share.

The Net SY of 7.96% places CME in the 6–7.99% band, with a score of 8.00. Overall remuneration is generous and structurally sustainable, supported by FCF that abundantly covers the regular quarterly dividend alone, with the variable dividend acting as discretionary distribution of excess cash.

Combined profile: Solid business, positive outlook, full valuation.

Competitive Advantage and Moat

CME's moat can be classified as a regulated monopoly with network effect — an extremely rare combination in the global corporate landscape. Concentrated liquidity on its markets creates a virtuous circle: more participants attract greater liquidity, which lowers spreads and reduces execution costs, which attracts further participants. This effect is stable and expanding: the continuous launch of new products (crypto futures, single stock futures, micro contracts) widens the perimeter of the moat without requiring significant capital investments. No credible scenarios of structural erosion are visible in the medium term.

General Cycle and Competitive Dynamics

The regulated derivatives sector is in an expansionary phase, with record aggregate volumes in 2025. CME gains share in absolute terms thanks to product innovation and international expansion, while pricing power remains high: proprietary contracts (SOFR futures, E-mini S&P 500) are de facto benchmarks for global markets and have no equivalent regulated alternatives. Competition from alternative exchanges — including decentralized venues — is monitored but does not represent a credible threat in the short-medium term for the core institutional segment.

Catalysts and Future Opportunities (Bull Case)

The launch of more than 50 single stock futures on S&P 500 and Nasdaq 100 stocks in the second half of 2026 represents a potentially significant incremental volume driver, opening a market that so far has been served only by OTC. Crypto expansion (AVAX, SUI, 24/7 trading from May 2026) captures the growing institutionalization of digital assets. Exploration of rare-earth futures, in a context of geopolitical tensions over the supply chain for critical materials, could open a completely new segment. Finally, higher rates on clearing cash balances generate additional interest income that does not depend on volumes.

Risks (Bear Case)

The main risk is a prolonged normalization of macro volatility — a "great moderation" scenario — that would compress volumes in the rates and index segments, which represent the most relevant share of revenue. A second risk is legislative pressure on market data and connectivity costs, traditionally slow but structurally present. Finally, any acute systemic shocks (flash crash, insolvency of large clearing members) could generate temporary liquidity dry-ups, although counterparty risk is mitigated by margin frameworks.

Solid business, fair valuation. Limited opportunity at the current price. NEUTRAL.

Why it could be an opportunity

CME is one of the very few listed companies in the world with a genuinely insurmountable moat and a business model that strengthens during periods of market turbulence — exactly when most portfolios suffer. Shareholder remuneration is generous (Net SY ~8%) and structurally sustainable. For an investor with a multi-year horizon, any significant correction in the stock represents a potentially interesting entry point into a company that is unlikely to lose systemic relevance.

Why it could be a risk

At the current price, the market already discounts the quality of the business without leaving a margin of safety relative to the weighted intrinsic fair value ($251.05). The sell-side consensus does not identify meaningful upside over the next 12 months, and the P/E of 26.5x is in line with the historical average — therefore offering no relative discount signal. An investor entering today pays a full price for an excellent company, with more limited return asymmetry than at lower prices.

Price Target Table

This analysis is produced by the Score³ system for informational purposes only and does not constitute financial advice, a solicitation to invest, or a trading or investment recommendation. Data is collected from public sources and may contain errors or delays. Fair value estimates and price targets are model-based projections subject to significant uncertainty and do not represent certain forecasts. Investing involves risks, including the possible loss of invested capital. Always verify critical data against primary sources before making any investment decision. Past performance is not indicative of future results.